CORT
CORCEPT THERAPEUTICS INC
Latest Form 4:Sale$3.3MbyPark Kimberly (Director) · filed Aug 28, 2026
CORCEPT THERAPEUTICS INC (CORT) has 85 SEC Form 4 filings (252 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Aug 28, 2026.
The most active filer is Chief Development Officer Guyer William with 15 filings. Insiders have net sold $65.1M over the trailing 6 months. The largest single insider purchase in this window was $3.3M by Director BAKER G LEONARD JR on Mar 17, 2026.
- Industry:Biotechnology
- CEO:Joseph K. Belanoff
- Employees:500
- HQ:Menlo Park, CA, US
- IPO:2004-04-14
Insider Buying
$3.3M
reported purchases (SEC code P)
Insider Selling
$97.1M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Market Cap
$12.3B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Park KimberlyFirst filing | Director | Sale | 26,685 | $3.3M | Aug 28 | SEC ↗ |
| See Remarks | Sale | 30,955 | $3.9M | Aug 27 | SEC ↗ | |
| Director | Sale | 103,606 | $12.3M | Aug 20 | SEC ↗ | |
| See Remarks | Sale | 3,664 | $419K | Aug 18 | SEC ↗ | |
| Director | Sale | 10,000 | $1.1M | Aug 18 | SEC ↗ | |
Robb Gary CharlesFirst filing | Chief Business Officer | Sale | 10,000 | $1.2M | Aug 18 | SEC ↗ |
| Chief Development Officer | Sale | 16,300 | $1.8M | Aug 12 | SEC ↗ | |
| See Remarks | Sale | 1,031 | $118K | Aug 12 | SEC ↗ | |
| Chief Development Officer | Sale | 3,700 | $419K | Aug 6 | SEC ↗ | |
| See Remarks | Sale | 20,305 | $2.3M | Aug 5 | SEC ↗ | |
| See Remarks | Sale | 1,540 | $176K | Aug 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 80,000 | $9.2M | Aug 3 | SEC ↗ | |
| Director | Sale | 10,000 | $883K | Jul 17 | SEC ↗ | |
| Chief Financial Officer | Sale | 40,000 | $3.5M | Jul 17 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $1.9M | Jul 8 | SEC ↗ | |
| See Remarks | Sale | 25,000 | $2.2M | Jul 6 | SEC ↗ | |
WILSON JAMES NFirst filing | Director | Sale | 10,000 | $832K | Jun 18 | SEC ↗ |
MAHONEY DAVID LFirst filing | Director | Sale | 20,000 | $1.7M | Jun 18 | SEC ↗ |
| Chief Financial Officer | Sale | 40,000 | $3.2M | Jun 17 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $1.4M | Jun 4 | SEC ↗ | |
| See Remarks | Sale | 25,000 | $1.8M | Jun 3 | SEC ↗ | |
Mokari AtabakFirst filing | Chief Financial Officer | Sale | 40,000 | $2.8M | Jun 3 | SEC ↗ |
| Chief Executive Officer | Sale | 12,837 | $895K | Jun 2 | SEC ↗ | |
Lyon Joseph DouglasFirst in 6 months | See Remarks | Sale | 5,000 | $325K | May 29 | SEC ↗ |
Maduck SeanFirst in 6 months | See Remarks | Sale | 75,000 | $4.9M | May 29 | SEC ↗ |
| Chief Development Officer | Sale | 20,000 | $1.0M | May 7 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $2.0M | May 5 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $819K | Apr 8 | SEC ↗ | |
BELANOFF JOSEPH KFirst in 4 months | Chief Executive Officer | Sale | 26,198 | $1.3M | Mar 27 | SEC ↗ |
| Chief Development Officer | Sale | 11,767 | $424K | Mar 24 | SEC ↗ | |
BAKER G LEONARD JRFirst filing | Director | Purchase | 100,000 | $3.3M | Mar 19 | SEC ↗ |
| Chief Development Officer | Sale | 8,233 | $296K | Mar 6 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $817K | Feb 5 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $704K | Jan 8 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $1.6M | Dec 3 | SEC ↗ | |
| See Remarks | Sale | 5,000 | $398K | Dec 3 | SEC ↗ | |
| See Remarks | Sale | 20,000 | $1.6M | Dec 3 | SEC ↗ | |
| Chief Development Officer | Sale | 4,500 | $364K | Dec 3 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.2M | Dec 3 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $1.5M | Nov 7 | SEC ↗ | |
| Chief Executive Officer | Sale | 11,218 | $831K | Nov 5 | SEC ↗ | |
| Chief Executive Officer | Sale | 28,782 | $2.2M | Nov 5 | SEC ↗ | |
| See Remarks | Sale | 20,000 | $1.5M | Nov 5 | SEC ↗ | |
| See Remarks | Sale | 5,000 | $368K | Nov 5 | SEC ↗ | |
| Director | Sale | 2,200 | $193K | Oct 15 | SEC ↗ | |
| Chief Development Officer | Sale | 20,000 | $1.8M | Oct 9 | SEC ↗ | |
| See Remarks | Sale | 20,000 | $1.7M | Oct 3 | SEC ↗ | |
| See Remarks | Sale | 5,000 | $424K | Oct 3 | SEC ↗ | |
| Chief Executive Officer | Sale | 40,000 | $3.4M | Oct 3 | SEC ↗ | |
Swisher Daniel N JRFirst filing | Director | Sale | 2,200 | $159K | Sep 11 | SEC ↗ |
Lyon Joseph DouglasFirst filing | See Remarks | Sale | 5,000 | $351K | Sep 4 | SEC ↗ |
Maduck SeanFirst filing | See Remarks | Sale | 20,000 | $1.4M | Sep 4 | SEC ↗ |
Guyer WilliamFirst filing | Chief Development Officer | Sale | 20,000 | $1.4M | Sep 4 | SEC ↗ |
BELANOFF JOSEPH KFirst filing | Chief Executive Officer | Sale | 40,000 | $2.8M | Sep 4 | SEC ↗ |
Related companies
CORCEPT THERAPEUTICS INC is in the Healthcare sector.